NDC 55513-141 – Kanjinti
Trastuzumab 150 mg/7.15mL · Injection, Powder, Lyophilized, For Solution · Intravenous
Product NDC55513-141
Product details
- Brand name
- Kanjinti
- Generic name
- trastuzumab-anns
- Labeler
- Amgen, Inc
- Dosage form
- Injection, Powder, Lyophilized, For Solution
- Route
- Intravenous
- Marketing category
- BLA · BLA761073
- Marketed since
- October 28, 2019
- Listing expires
- December 31, 2027
- Pharmacologic class
- HER2/neu Receptor Antagonist
Active ingredients
- Trastuzumab 150 mg/7.15mL
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 55513-141-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-141-01) / 7.15 mL in 1 VIAL, SINGLE-DOSE | Oct 28, 2019 |
| 55513-141-21 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-141-21) / 7.15 mL in 1 VIAL, SINGLE-DOSE | Jul 1, 2025 |
Other Kanjinti products
- 55513-132 Trastuzumab 420 mg/20mL · Injection, Powder, Lyophilized, For Solution · Amgen, Inc